#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3 .
1-1	0-1	3	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Protein and Peptide Nanobiosensors for the Early Diagnosis of Diseases
2-1	4-11	Protein	substance	new	coref	7-5
2-2	12-15	and	_	_	_	_
2-3	16-23	Peptide	place|object[4]	new|new[4]	coref|coref|coref|coref	6-16[38_4]|15-26|6-16[38_4]|15-26
2-4	24-38	Nanobiosensors	object[4]	new[4]	_	_
2-5	39-42	for	object[4]	new[4]	_	_
2-6	43-46	the	object[4]|abstract[5]	new[4]|new[5]	coref	5-12[28_5]
2-7	47-52	Early	object[4]|abstract[5]	new[4]|new[5]	_	_
2-8	53-62	Diagnosis	object[4]|abstract[5]	new[4]|new[5]	_	_
2-9	63-65	of	object[4]|abstract[5]	new[4]|new[5]	_	_
2-10	66-74	Diseases	object[4]|abstract[5]|abstract	new[4]|new[5]|new	coref	5-16

#Text=A pathological process at an early stage is characterized by the appearance of marker proteins at very low ( 10−15 M and lower ) concentrations in blood , and highly-sensitive nanobiosensor systems are required to detect proteins at such low concentrations .
3-1	75-76	A	abstract[7]	new[7]	_	_
3-2	77-89	pathological	abstract[7]	new[7]	_	_
3-3	90-97	process	abstract[7]	new[7]	_	_
3-4	98-100	at	abstract[7]	new[7]	_	_
3-5	101-103	an	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-6	104-109	early	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-7	110-115	stage	abstract[7]|abstract[8]	new[7]|new[8]	_	_
3-8	116-118	is	_	_	_	_
3-9	119-132	characterized	_	_	_	_
3-10	133-135	by	_	_	_	_
3-11	136-139	the	abstract[9]	new[9]	_	_
3-12	140-150	appearance	abstract[9]	new[9]	_	_
3-13	151-153	of	abstract[9]	new[9]	_	_
3-14	154-160	marker	abstract[9]|substance[10]	new[9]|new[10]	coref	3-37[0_10]
3-15	161-169	proteins	abstract[9]|substance[10]	new[9]|new[10]	_	_
3-16	170-172	at	abstract[9]	new[9]	_	_
3-17	173-177	very	abstract[9]	new[9]	_	_
3-18	178-181	low	abstract[9]	new[9]	_	_
3-19	182-183	(	abstract[9]	new[9]	_	_
3-20	184-189	10−15	abstract[9]|quantity[11]	new[9]|new[11]	_	_
3-21	190-191	M	abstract[9]|quantity[11]	new[9]|new[11]	_	_
3-22	192-195	and	abstract[9]	new[9]	_	_
3-23	196-201	lower	abstract[9]	new[9]	_	_
3-24	202-203	)	abstract[9]	new[9]	_	_
3-25	204-218	concentrations	abstract[9]|animal[12]	new[9]|new[12]	coref	3-39[17_12]
3-26	219-221	in	abstract[9]|animal[12]	new[9]|new[12]	_	_
3-27	222-227	blood	abstract[9]|animal[12]|substance	new[9]|new[12]|new	_	_
3-28	228-229	,	_	_	_	_
3-29	230-233	and	_	_	_	_
3-30	234-250	highly-sensitive	object[15]	new[15]	coref	17-7[228_15]
3-31	251-264	nanobiosensor	person|object[15]	new|new[15]	_	_
3-32	265-272	systems	object[15]	new[15]	_	_
3-33	273-276	are	_	_	_	_
3-34	277-285	required	_	_	_	_
3-35	286-288	to	_	_	_	_
3-36	289-295	detect	_	_	_	_
3-37	296-304	proteins	substance	giv	coref	6-62[52_0]
3-38	305-307	at	_	_	_	_
3-39	308-312	such	animal[17]	giv[17]	coref	7-7[63_17]
3-40	313-316	low	animal[17]	giv[17]	_	_
3-41	317-331	concentrations	animal[17]	giv[17]	_	_
3-42	332-333	.	_	_	_	_

#Text=Additionally , the composition of biomolecules gathering at a surface is another relevant issue , given the dynamic nature of disease progression .
4-1	334-346	Additionally	_	_	_	_
4-2	347-348	,	_	_	_	_
4-3	349-352	the	abstract[18]	new[18]	coref	4-12[21_18]
4-4	353-364	composition	abstract[18]	new[18]	_	_
4-5	365-367	of	abstract[18]	new[18]	_	_
4-6	368-380	biomolecules	abstract[18]|substance	new[18]|new	_	_
4-7	381-390	gathering	_	_	_	_
4-8	391-393	at	_	_	_	_
4-9	394-395	a	place[20]	new[20]	coref	12-27[0_20]
4-10	396-403	surface	place[20]	new[20]	_	_
4-11	404-406	is	_	_	_	_
4-12	407-414	another	abstract[21]	giv[21]	coref	13-24[169_21]
4-13	415-423	relevant	abstract[21]	giv[21]	_	_
4-14	424-429	issue	abstract[21]	giv[21]	_	_
4-15	430-431	,	_	_	_	_
4-16	432-437	given	_	_	_	_
4-17	438-441	the	abstract[22]	new[22]	_	_
4-18	442-449	dynamic	abstract[22]	new[22]	_	_
4-19	450-456	nature	abstract[22]	new[22]	_	_
4-20	457-459	of	abstract[22]	new[22]	_	_
4-21	460-467	disease	abstract[22]|abstract|abstract[24]	new[22]|new|new[24]	_	_
4-22	468-479	progression	abstract[22]|abstract[24]	new[22]|new[24]	_	_
4-23	480-481	.	_	_	_	_

#Text=With respect to that , nano-biosensors may offer increased possibilities for the early diagnosis of diseases .
5-1	482-486	With	_	_	_	_
5-2	487-494	respect	abstract[25]	new[25]	_	_
5-3	495-497	to	abstract[25]	new[25]	_	_
5-4	498-502	that	abstract[25]	new[25]	_	_
5-5	503-504	,	_	_	_	_
5-6	505-520	nano-biosensors	object	new	_	_
5-7	521-524	may	_	_	_	_
5-8	525-530	offer	_	_	_	_
5-9	531-540	increased	abstract[27]	new[27]	_	_
5-10	541-554	possibilities	abstract[27]	new[27]	_	_
5-11	555-558	for	abstract[27]	new[27]	_	_
5-12	559-562	the	abstract[27]|abstract[28]	new[27]|giv[28]	_	_
5-13	563-568	early	abstract[27]|abstract[28]	new[27]|giv[28]	_	_
5-14	569-578	diagnosis	abstract[27]|abstract[28]	new[27]|giv[28]	_	_
5-15	579-581	of	abstract[27]|abstract[28]	new[27]|giv[28]	_	_
5-16	582-590	diseases	abstract[27]|abstract[28]|abstract	new[27]|giv[28]|giv	_	_
5-17	591-592	.	_	_	_	_

#Text=In the manuscript : Influence of Chip Materials on Charge Generation in Flowing Solution in Nanobiosensors , Y.D. Ivanov and coworkers demonstrate that the presence of an AFM chip ( made of mica and graphite ) near the nozzle of the injector supplying an analyte solution into the measuring cell of an AFM-based fishing system ( used for the registration of low-abundant proteins in the temperature range corresponding to the physiological temperature of 35 °C ) causes an increase in charge generation upon the injection of the solution .
6-1	593-595	In	_	_	_	_
6-2	596-599	the	object[30]	new[30]	_	_
6-3	600-610	manuscript	object[30]	new[30]	_	_
6-4	611-612	:	_	_	_	_
6-5	613-622	Influence	abstract[31]	new[31]	_	_
6-6	623-625	of	abstract[31]	new[31]	_	_
6-7	626-630	Chip	abstract[31]|object|object[33]	new[31]|new|new[33]	_	_
6-8	631-640	Materials	abstract[31]|object[33]	new[31]|new[33]	_	_
6-9	641-643	on	abstract[31]	new[31]	_	_
6-10	644-650	Charge	abstract[31]|person|abstract[35]	new[31]|new|new[35]	coref|coref	6-81[58_35]|6-81[58_35]
6-11	651-661	Generation	abstract[31]|abstract[35]	new[31]|new[35]	_	_
6-12	662-664	in	abstract[31]|abstract[35]	new[31]|new[35]	_	_
6-13	665-672	Flowing	abstract[31]|abstract[35]|substance[36]	new[31]|new[35]|new[36]	coref	6-44[47_36]
6-14	673-681	Solution	abstract[31]|abstract[35]|substance[36]	new[31]|new[35]|new[36]	_	_
6-15	682-684	in	abstract[31]|abstract[35]|substance[36]	new[31]|new[35]|new[36]	_	_
6-16	685-699	Nanobiosensors	abstract[31]|abstract[35]|substance[36]|object|object[38]	new[31]|new[35]|new[36]|new|giv[38]	_	_
6-17	700-701	,	abstract[31]|abstract[35]|substance[36]|object[38]	new[31]|new[35]|new[36]|giv[38]	_	_
6-18	702-706	Y.D.	abstract[31]|abstract[35]|substance[36]|object[38]|person[39]	new[31]|new[35]|new[36]|giv[38]|new[39]	_	_
6-19	707-713	Ivanov	abstract[31]|abstract[35]|substance[36]|object[38]|person[39]	new[31]|new[35]|new[36]|giv[38]|new[39]	_	_
6-20	714-717	and	abstract[31]|abstract[35]|substance[36]|object[38]	new[31]|new[35]|new[36]|giv[38]	_	_
6-21	718-727	coworkers	abstract[31]|abstract[35]|substance[36]|object[38]|person	new[31]|new[35]|new[36]|giv[38]|new	coref	8-4[70_0]
6-22	728-739	demonstrate	_	_	_	_
6-23	740-744	that	_	_	_	_
6-24	745-748	the	abstract[41]	new[41]	_	_
6-25	749-757	presence	abstract[41]	new[41]	_	_
6-26	758-760	of	abstract[41]	new[41]	_	_
6-27	761-763	an	abstract[41]|object[42]	new[41]|new[42]	_	_
6-28	764-767	AFM	abstract[41]|object[42]	new[41]|new[42]	_	_
6-29	768-772	chip	abstract[41]|object[42]	new[41]|new[42]	_	_
6-30	773-774	(	_	_	_	_
6-31	775-779	made	_	_	_	_
6-32	780-782	of	_	_	_	_
6-33	783-787	mica	substance	new	_	_
6-34	788-791	and	_	_	_	_
6-35	792-800	graphite	abstract	new	_	_
6-36	801-802	)	_	_	_	_
6-37	803-807	near	_	_	_	_
6-38	808-811	the	object[45]	new[45]	_	_
6-39	812-818	nozzle	object[45]	new[45]	_	_
6-40	819-821	of	object[45]	new[45]	_	_
6-41	822-825	the	object[45]|object[46]	new[45]|new[46]	coref	7-19[68_46]
6-42	826-834	injector	object[45]|object[46]	new[45]|new[46]	_	_
6-43	835-844	supplying	_	_	_	_
6-44	845-847	an	substance[47]	giv[47]	coref	6-87[60_47]
6-45	848-855	analyte	substance[47]	giv[47]	_	_
6-46	856-864	solution	substance[47]	giv[47]	_	_
6-47	865-869	into	substance[47]	giv[47]	_	_
6-48	870-873	the	substance[47]|object[48]	giv[47]|new[48]	_	_
6-49	874-883	measuring	substance[47]|object[48]	giv[47]|new[48]	_	_
6-50	884-888	cell	substance[47]|object[48]	giv[47]|new[48]	_	_
6-51	889-891	of	substance[47]|object[48]	giv[47]|new[48]	_	_
6-52	892-894	an	substance[47]|object[48]|abstract[50]	giv[47]|new[48]|new[50]	_	_
6-53	895-904	AFM-based	substance[47]|object[48]|abstract[50]	giv[47]|new[48]|new[50]	_	_
6-54	905-912	fishing	substance[47]|object[48]|object|abstract[50]	giv[47]|new[48]|new|new[50]	_	_
6-55	913-919	system	substance[47]|object[48]|abstract[50]	giv[47]|new[48]|new[50]	_	_
6-56	920-921	(	_	_	_	_
6-57	922-926	used	_	_	_	_
6-58	927-930	for	_	_	_	_
6-59	931-934	the	abstract[51]	new[51]	_	_
6-60	935-947	registration	abstract[51]	new[51]	_	_
6-61	948-950	of	abstract[51]	new[51]	_	_
6-62	951-963	low-abundant	abstract[51]|substance[52]	new[51]|giv[52]	_	_
6-63	964-972	proteins	abstract[51]|substance[52]	new[51]|giv[52]	_	_
6-64	973-975	in	abstract[51]	new[51]	_	_
6-65	976-979	the	abstract[51]|abstract[54]	new[51]|new[54]	coref	12-45[155_54]
6-66	980-991	temperature	abstract[51]|abstract|abstract[54]	new[51]|new|new[54]	coref	6-70[55_0]
6-67	992-997	range	abstract[51]|abstract[54]	new[51]|new[54]	_	_
6-68	998-1011	corresponding	_	_	_	_
6-69	1012-1014	to	_	_	_	_
6-70	1015-1018	the	abstract[55]	giv[55]	_	_
6-71	1019-1032	physiological	abstract[55]	giv[55]	_	_
6-72	1033-1044	temperature	abstract[55]	giv[55]	_	_
6-73	1045-1047	of	abstract[55]	giv[55]	_	_
6-74	1048-1050	35	abstract[55]|quantity[56]	giv[55]|new[56]	_	_
6-75	1051-1053	°C	abstract[55]|quantity[56]	giv[55]|new[56]	_	_
6-76	1054-1055	)	_	_	_	_
6-77	1056-1062	causes	_	_	_	_
6-78	1063-1065	an	abstract[57]	new[57]	coref	7-10[64_57]
6-79	1066-1074	increase	abstract[57]	new[57]	_	_
6-80	1075-1077	in	abstract[57]	new[57]	_	_
6-81	1078-1084	charge	abstract[57]|abstract[58]	new[57]|giv[58]	coref	7-16[67_58]
6-82	1085-1095	generation	abstract[57]|abstract[58]	new[57]|giv[58]	_	_
6-83	1096-1100	upon	abstract[57]|abstract[58]	new[57]|giv[58]	_	_
6-84	1101-1104	the	abstract[57]|abstract[58]|event[59]	new[57]|giv[58]|new[59]	_	_
6-85	1105-1114	injection	abstract[57]|abstract[58]|event[59]	new[57]|giv[58]|new[59]	_	_
6-86	1115-1117	of	abstract[57]|abstract[58]|event[59]	new[57]|giv[58]|new[59]	_	_
6-87	1118-1121	the	abstract[57]|abstract[58]|event[59]|substance[60]	new[57]|giv[58]|new[59]|giv[60]	_	_
6-88	1122-1130	solution	abstract[57]|abstract[58]|event[59]|substance[60]	new[57]|giv[58]|new[59]|giv[60]	_	_
6-89	1131-1132	.	_	_	_	_

#Text=In the presence of protein at femtomolar concentrations , an increase in the efficiency of charge generation in the injector was demonstrated .
7-1	1133-1135	In	_	_	_	_
7-2	1136-1139	the	abstract[61]	new[61]	_	_
7-3	1140-1148	presence	abstract[61]	new[61]	_	_
7-4	1149-1151	of	abstract[61]	new[61]	_	_
7-5	1152-1159	protein	abstract[61]|substance	new[61]|giv	coref	19-45
7-6	1160-1162	at	abstract[61]	new[61]	_	_
7-7	1163-1173	femtomolar	abstract[61]|animal[63]	new[61]|giv[63]	_	_
7-8	1174-1188	concentrations	abstract[61]|animal[63]	new[61]|giv[63]	_	_
7-9	1189-1190	,	_	_	_	_
7-10	1191-1193	an	abstract[64]	giv[64]	_	_
7-11	1194-1202	increase	abstract[64]	giv[64]	_	_
7-12	1203-1205	in	abstract[64]	giv[64]	_	_
7-13	1206-1209	the	abstract[64]|abstract[65]	giv[64]|new[65]	_	_
7-14	1210-1220	efficiency	abstract[64]|abstract[65]	giv[64]|new[65]	_	_
7-15	1221-1223	of	abstract[64]|abstract[65]	giv[64]|new[65]	_	_
7-16	1224-1230	charge	abstract[64]|abstract[65]|abstract|abstract[67]	giv[64]|new[65]|new|giv[67]	_	_
7-17	1231-1241	generation	abstract[64]|abstract[65]|abstract[67]	giv[64]|new[65]|giv[67]	_	_
7-18	1242-1244	in	abstract[64]|abstract[65]|abstract[67]	giv[64]|new[65]|giv[67]	_	_
7-19	1245-1248	the	abstract[64]|abstract[65]|abstract[67]|object[68]	giv[64]|new[65]|giv[67]|giv[68]	_	_
7-20	1249-1257	injector	abstract[64]|abstract[65]|abstract[67]|object[68]	giv[64]|new[65]|giv[67]|giv[68]	_	_
7-21	1258-1261	was	_	_	_	_
7-22	1262-1274	demonstrated	_	_	_	_
7-23	1275-1276	.	_	_	_	_

#Text=G.Z. Gayda and coworkers in their paper on Metallic Nanoparticles Obtained via “ Green ” Synthesis as a Platform for Biosensor Construction demonstrate the possibility of developing reagent-less , enzyme-based amperometric biosensors using metallic nanoparticles obtained via green synthesis ( gNPs ) , which have great potential for applications in biotechnology , industry , and medicine as antibacterial agents , fluorescent markers , and carriers for drug delivery , respectively .
8-1	1277-1281	G.Z.	person[69]	new[69]	_	_
8-2	1282-1287	Gayda	person[69]	new[69]	_	_
8-3	1288-1291	and	_	_	_	_
8-4	1292-1301	coworkers	person[70]	giv[70]	coref	11-33[0_70]
8-5	1302-1304	in	person[70]	giv[70]	_	_
8-6	1305-1310	their	person[70]|abstract[71]	giv[70]|new[71]	coref	14-6[177_71]
8-7	1311-1316	paper	person[70]|abstract[71]	giv[70]|new[71]	_	_
8-8	1317-1319	on	person[70]|abstract[71]	giv[70]|new[71]	_	_
8-9	1320-1328	Metallic	person[70]|abstract[71]|object[72]	giv[70]|new[71]|new[72]	coref	8-34[81_72]
8-10	1329-1342	Nanoparticles	person[70]|abstract[71]|object[72]	giv[70]|new[71]|new[72]	_	_
8-11	1343-1351	Obtained	_	_	_	_
8-12	1352-1355	via	_	_	_	_
8-13	1356-1357	“	abstract[74]	new[74]	coref	8-38[82_74]
8-14	1358-1363	Green	person|abstract[74]	new|new[74]	_	_
8-15	1364-1365	”	abstract[74]	new[74]	_	_
8-16	1366-1375	Synthesis	abstract[74]	new[74]	_	_
8-17	1376-1378	as	abstract[74]	new[74]	_	_
8-18	1379-1380	a	abstract[74]	new[74]	_	_
8-19	1381-1389	Platform	abstract[74]	new[74]	_	_
8-20	1390-1393	for	abstract[74]	new[74]	_	_
8-21	1394-1403	Biosensor	abstract[74]|place|place[76]	new[74]|new|new[76]	coref|coref	19-7|19-7
8-22	1404-1416	Construction	abstract[74]|place[76]	new[74]|new[76]	_	_
8-23	1417-1428	demonstrate	_	_	_	_
8-24	1429-1432	the	abstract[77]	new[77]	_	_
8-25	1433-1444	possibility	abstract[77]	new[77]	_	_
8-26	1445-1447	of	_	_	_	_
8-27	1448-1458	developing	_	_	_	_
8-28	1459-1471	reagent-less	object	new	_	_
8-29	1472-1473	,	_	_	_	_
8-30	1474-1486	enzyme-based	_	_	_	_
8-31	1487-1499	amperometric	abstract|substance[80]	new|new[80]	coref|coref	10-49[117_80]|10-49[117_80]
8-32	1500-1510	biosensors	substance[80]	new[80]	_	_
8-33	1511-1516	using	_	_	_	_
8-34	1517-1525	metallic	object[81]	giv[81]	coref	14-15[181_81]
8-35	1526-1539	nanoparticles	object[81]	giv[81]	_	_
8-36	1540-1548	obtained	_	_	_	_
8-37	1549-1552	via	_	_	_	_
8-38	1553-1558	green	abstract[82]	giv[82]	appos	8-41[0_82]
8-39	1559-1568	synthesis	abstract[82]	giv[82]	_	_
8-40	1569-1570	(	_	_	_	_
8-41	1571-1575	gNPs	abstract	giv	coref	9-5[94_0]
8-42	1576-1577	)	_	_	_	_
8-43	1578-1579	,	_	_	_	_
8-44	1580-1585	which	_	_	_	_
8-45	1586-1590	have	_	_	_	_
8-46	1591-1596	great	abstract[84]	new[84]	_	_
8-47	1597-1606	potential	abstract[84]	new[84]	_	_
8-48	1607-1610	for	abstract[84]	new[84]	_	_
8-49	1611-1623	applications	abstract[84]|abstract[85]	new[84]|new[85]	coref	14-35[190_85]
8-50	1624-1626	in	abstract[84]|abstract[85]	new[84]|new[85]	_	_
8-51	1627-1640	biotechnology	abstract[84]|abstract[85]|abstract	new[84]|new[85]|new	_	_
8-52	1641-1642	,	abstract[84]|abstract[85]	new[84]|new[85]	_	_
8-53	1643-1651	industry	abstract[84]|abstract[85]|abstract	new[84]|new[85]|new	_	_
8-54	1652-1653	,	abstract[84]|abstract[85]	new[84]|new[85]	_	_
8-55	1654-1657	and	abstract[84]|abstract[85]	new[84]|new[85]	_	_
8-56	1658-1666	medicine	abstract[84]|abstract[85]|abstract[88]	new[84]|new[85]|new[88]	_	_
8-57	1667-1669	as	abstract[84]|abstract[85]|abstract[88]	new[84]|new[85]|new[88]	_	_
8-58	1670-1683	antibacterial	abstract[84]|abstract[85]|abstract[88]	new[84]|new[85]|new[88]	_	_
8-59	1684-1690	agents	abstract[84]|abstract[85]|abstract[88]	new[84]|new[85]|new[88]	_	_
8-60	1691-1692	,	abstract[84]|abstract[85]|abstract[88]	new[84]|new[85]|new[88]	_	_
8-61	1693-1704	fluorescent	abstract[84]|abstract[85]|abstract[88]	new[84]|new[85]|new[88]	_	_
8-62	1705-1712	markers	abstract[84]|abstract[85]|abstract[88]	new[84]|new[85]|new[88]	_	_
8-63	1713-1714	,	_	_	_	_
8-64	1715-1718	and	_	_	_	_
8-65	1719-1727	carriers	organization[89]	new[89]	_	_
8-66	1728-1731	for	organization[89]	new[89]	_	_
8-67	1732-1736	drug	organization[89]|substance|abstract[91]	new[89]|new|new[91]	_	_
8-68	1737-1745	delivery	organization[89]|abstract[91]	new[89]|new[91]	_	_
8-69	1746-1747	,	organization[89]	new[89]	_	_
8-70	1748-1760	respectively	organization[89]	new[89]	_	_
8-71	1761-1762	.	_	_	_	_

#Text=The bioelectrodes modified with Pd-based gNPs have lower sensitivities to their substrates , but broader linear ranges of their detection and higher storage stabilities than unmodified control electrodes .
9-1	1763-1766	The	substance[92]	new[92]	_	_
9-2	1767-1780	bioelectrodes	substance[92]	new[92]	_	_
9-3	1781-1789	modified	_	_	_	_
9-4	1790-1794	with	_	_	_	_
9-5	1795-1803	Pd-based	abstract|abstract[94]	new|giv[94]	coref|coref	10-23[111_94]|10-23[111_94]
9-6	1804-1808	gNPs	abstract[94]	giv[94]	_	_
9-7	1809-1813	have	_	_	_	_
9-8	1814-1819	lower	abstract[95]|abstract[96]	new[95]|new[96]	_	_
9-9	1820-1833	sensitivities	abstract[95]|abstract[96]	new[95]|new[96]	_	_
9-10	1834-1836	to	abstract[95]|abstract[96]	new[95]|new[96]	_	_
9-11	1837-1842	their	abstract[95]|abstract[96]|object[97]	new[95]|new[96]|new[97]	_	_
9-12	1843-1853	substrates	abstract[95]|abstract[96]|object[97]	new[95]|new[96]|new[97]	_	_
9-13	1854-1855	,	abstract[96]	new[96]	_	_
9-14	1856-1859	but	abstract[96]	new[96]	_	_
9-15	1860-1867	broader	abstract[96]|abstract[98]	new[96]|new[98]	_	_
9-16	1868-1874	linear	abstract[96]|abstract[98]	new[96]|new[98]	_	_
9-17	1875-1881	ranges	abstract[96]|abstract[98]	new[96]|new[98]	_	_
9-18	1882-1884	of	abstract[96]|abstract[98]	new[96]|new[98]	_	_
9-19	1885-1890	their	abstract[96]|abstract[98]|abstract[99]	new[96]|new[98]|new[99]	coref	14-19[183_99]
9-20	1891-1900	detection	abstract[96]|abstract[98]|abstract[99]	new[96]|new[98]|new[99]	_	_
9-21	1901-1904	and	abstract[96]|abstract[98]	new[96]|new[98]	_	_
9-22	1905-1911	higher	abstract[96]|abstract[98]|abstract[101]	new[96]|new[98]|new[101]	_	_
9-23	1912-1919	storage	abstract[96]|abstract[98]|place|abstract[101]	new[96]|new[98]|new|new[101]	_	_
9-24	1920-1931	stabilities	abstract[96]|abstract[98]|abstract[101]	new[96]|new[98]|new[101]	_	_
9-25	1932-1936	than	abstract[96]|abstract[98]|abstract[101]	new[96]|new[98]|new[101]	_	_
9-26	1937-1947	unmodified	abstract[96]|abstract[98]|abstract[101]|object[103]	new[96]|new[98]|new[101]|new[103]	coref	20-4[263_103]
9-27	1948-1955	control	abstract[96]|abstract[98]|abstract[101]|abstract|object[103]	new[96]|new[98]|new[101]|new|new[103]	_	_
9-28	1956-1966	electrodes	abstract[96]|abstract[98]|abstract[101]|object[103]	new[96]|new[98]|new[101]|new[103]	_	_
9-29	1967-1968	.	_	_	_	_

#Text=Moreover , the advantage of the “ green ” approach is the rapid growth of the yeast cells with a high-yield of pure gNPs surrounded by organic compounds that provides the anti-aggregative effect on metallic gNPs , which can be useful as carriers of enzymes and cells in biosensors and biofuel cells .
10-1	1969-1977	Moreover	_	_	_	_
10-2	1978-1979	,	_	_	_	_
10-3	1980-1983	the	abstract[104]	new[104]	coref	10-12[107_104]
10-4	1984-1993	advantage	abstract[104]	new[104]	_	_
10-5	1994-1996	of	abstract[104]	new[104]	_	_
10-6	1997-2000	the	abstract[104]|abstract[106]	new[104]|new[106]	_	_
10-7	2001-2002	“	abstract[104]|abstract[106]	new[104]|new[106]	_	_
10-8	2003-2008	green	abstract[104]|abstract|abstract[106]	new[104]|new|new[106]	_	_
10-9	2009-2010	”	abstract[104]|abstract[106]	new[104]|new[106]	_	_
10-10	2011-2019	approach	abstract[104]|abstract[106]	new[104]|new[106]	_	_
10-11	2020-2022	is	_	_	_	_
10-12	2023-2026	the	abstract[107]	giv[107]	_	_
10-13	2027-2032	rapid	abstract[107]	giv[107]	_	_
10-14	2033-2039	growth	abstract[107]	giv[107]	_	_
10-15	2040-2042	of	abstract[107]	giv[107]	_	_
10-16	2043-2046	the	abstract[107]|object[109]	giv[107]|new[109]	coref	10-47[116_109]
10-17	2047-2052	yeast	abstract[107]|substance|object[109]	giv[107]|new|new[109]	_	_
10-18	2053-2058	cells	abstract[107]|object[109]	giv[107]|new[109]	_	_
10-19	2059-2063	with	abstract[107]|object[109]	giv[107]|new[109]	_	_
10-20	2064-2065	a	abstract[107]|object[109]|quantity[110]	giv[107]|new[109]|new[110]	_	_
10-21	2066-2076	high-yield	abstract[107]|object[109]|quantity[110]	giv[107]|new[109]|new[110]	_	_
10-22	2077-2079	of	abstract[107]|object[109]|quantity[110]	giv[107]|new[109]|new[110]	_	_
10-23	2080-2084	pure	abstract[107]|object[109]|quantity[110]|abstract[111]	giv[107]|new[109]|new[110]|giv[111]	coref	10-35[114_111]
10-24	2085-2089	gNPs	abstract[107]|object[109]|quantity[110]|abstract[111]	giv[107]|new[109]|new[110]|giv[111]	_	_
10-25	2090-2100	surrounded	_	_	_	_
10-26	2101-2103	by	_	_	_	_
10-27	2104-2111	organic	substance[112]	new[112]	_	_
10-28	2112-2121	compounds	substance[112]	new[112]	_	_
10-29	2122-2126	that	_	_	_	_
10-30	2127-2135	provides	_	_	_	_
10-31	2136-2139	the	abstract[113]	new[113]	_	_
10-32	2140-2156	anti-aggregative	abstract[113]	new[113]	_	_
10-33	2157-2163	effect	abstract[113]	new[113]	_	_
10-34	2164-2166	on	abstract[113]	new[113]	_	_
10-35	2167-2175	metallic	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
10-36	2176-2180	gNPs	abstract[113]|abstract[114]	new[113]|giv[114]	_	_
10-37	2181-2182	,	_	_	_	_
10-38	2183-2188	which	_	_	_	_
10-39	2189-2192	can	_	_	_	_
10-40	2193-2195	be	_	_	_	_
10-41	2196-2202	useful	_	_	_	_
10-42	2203-2205	as	_	_	_	_
10-43	2206-2214	carriers	_	_	_	_
10-44	2215-2217	of	_	_	_	_
10-45	2218-2225	enzymes	substance	new	_	_
10-46	2226-2229	and	_	_	_	_
10-47	2230-2235	cells	object[116]	giv[116]	coref	21-18[274_116]
10-48	2236-2238	in	object[116]	giv[116]	_	_
10-49	2239-2249	biosensors	object[116]|substance[117]	giv[116]|giv[117]	coref	19-25[0_117]
10-50	2250-2253	and	object[116]|substance[117]	giv[116]|giv[117]	_	_
10-51	2254-2261	biofuel	object[116]|substance[117]	giv[116]|giv[117]	_	_
10-52	2262-2267	cells	object[116]|substance[117]	giv[116]|giv[117]	_	_
10-53	2268-2269	.	_	_	_	_

#Text=In the article on The Characterisation and Quantification of Immobilised Concanavalin A on Quartz Surfaces Based on The Competitive Binding to Glucose and Fluorescent Labelled Dextran authored by T. Bich Hoang and coworkers , a simple protocol for the immobilization of Concanavalin A ( Con A ) on a quartz substrate , a common material for gravimetric microsensors , was developed .
11-1	2270-2272	In	_	_	_	_
11-2	2273-2276	the	abstract[118]	new[118]	_	_
11-3	2277-2284	article	abstract[118]	new[118]	_	_
11-4	2285-2287	on	abstract[118]	new[118]	_	_
11-5	2288-2291	The	abstract[118]|abstract[119]	new[118]|new[119]	_	_
11-6	2292-2308	Characterisation	abstract[118]|abstract[119]	new[118]|new[119]	_	_
11-7	2309-2312	and	abstract[118]	new[118]	_	_
11-8	2313-2327	Quantification	abstract[118]|abstract[120]	new[118]|new[120]	_	_
11-9	2328-2330	of	abstract[118]|abstract[120]	new[118]|new[120]	_	_
11-10	2331-2342	Immobilised	abstract[118]|abstract[120]|abstract|substance[122]	new[118]|new[120]|new|new[122]	coref|coref	11-42[0_122]|11-42[0_122]
11-11	2343-2355	Concanavalin	abstract[118]|abstract[120]|substance[122]	new[118]|new[120]|new[122]	_	_
11-12	2356-2357	A	abstract[118]|abstract[120]|substance[122]|object[124]	new[118]|new[120]|new[122]|new[124]	_	_
11-13	2358-2360	on	abstract[118]|abstract[120]|substance[122]|object[124]	new[118]|new[120]|new[122]|new[124]	_	_
11-14	2361-2367	Quartz	abstract[118]|abstract[120]|substance[122]|abstract|object[124]	new[118]|new[120]|new[122]|new|new[124]	coref	11-50
11-15	2368-2376	Surfaces	abstract[118]|abstract[120]|substance[122]|object[124]	new[118]|new[120]|new[122]|new[124]	_	_
11-16	2377-2382	Based	_	_	_	_
11-17	2383-2385	on	_	_	_	_
11-18	2386-2389	The	abstract[125]	new[125]	_	_
11-19	2390-2401	Competitive	abstract[125]	new[125]	_	_
11-20	2402-2409	Binding	object[126]	new[126]	coref	12-2[0_126]
11-21	2410-2412	to	object[126]	new[126]	_	_
11-22	2413-2420	Glucose	object[126]|substance	new[126]|new	coref	12-46
11-23	2421-2424	and	object[126]	new[126]	_	_
11-24	2425-2436	Fluorescent	object[126]|abstract	new[126]|new	_	_
11-25	2437-2445	Labelled	object[126]|abstract|substance[130]	new[126]|new|new[130]	coref|coref	12-18[0_130]|12-18[0_130]
11-26	2446-2453	Dextran	object[126]|substance[130]	new[126]|new[130]	_	_
11-27	2454-2462	authored	_	_	_	_
11-28	2463-2465	by	_	_	_	_
11-29	2466-2468	T.	person[131]	new[131]	_	_
11-30	2469-2473	Bich	person[131]	new[131]	_	_
11-31	2474-2479	Hoang	person[131]	new[131]	_	_
11-32	2480-2483	and	_	_	_	_
11-33	2484-2493	coworkers	person	giv	coref	14-4[176_0]
11-34	2494-2495	,	_	_	_	_
11-35	2496-2497	a	abstract[133]	new[133]	_	_
11-36	2498-2504	simple	abstract[133]	new[133]	_	_
11-37	2505-2513	protocol	abstract[133]	new[133]	_	_
11-38	2514-2517	for	abstract[133]	new[133]	_	_
11-39	2518-2521	the	abstract[133]|abstract[134]	new[133]|new[134]	_	_
11-40	2522-2536	immobilization	abstract[133]|abstract[134]	new[133]|new[134]	_	_
11-41	2537-2539	of	abstract[133]|abstract[134]	new[133]|new[134]	_	_
11-42	2540-2552	Concanavalin	abstract[133]|abstract[134]|substance	new[133]|new[134]|giv	_	_
11-43	2553-2554	A	abstract[133]|abstract[134]	new[133]|new[134]	_	_
11-44	2555-2556	(	abstract[133]|abstract[134]	new[133]|new[134]	_	_
11-45	2557-2560	Con	abstract[133]|abstract[134]|person[136]	new[133]|new[134]|new[136]	_	_
11-46	2561-2562	A	abstract[133]|abstract[134]|person[136]	new[133]|new[134]|new[136]	_	_
11-47	2563-2564	)	abstract[133]|abstract[134]	new[133]|new[134]	_	_
11-48	2565-2567	on	abstract[133]|abstract[134]	new[133]|new[134]	_	_
11-49	2568-2569	a	abstract[133]|abstract[134]|object[138]	new[133]|new[134]|new[138]	appos	11-53[139_138]
11-50	2570-2576	quartz	abstract[133]|abstract[134]|substance|object[138]	new[133]|new[134]|giv|new[138]	_	_
11-51	2577-2586	substrate	abstract[133]|abstract[134]|object[138]	new[133]|new[134]|new[138]	_	_
11-52	2587-2588	,	_	_	_	_
11-53	2589-2590	a	object[139]	giv[139]	coref	20-4[0_139]
11-54	2591-2597	common	object[139]	giv[139]	_	_
11-55	2598-2606	material	object[139]	giv[139]	_	_
11-56	2607-2610	for	object[139]	giv[139]	_	_
11-57	2611-2622	gravimetric	object[139]|object[140]	giv[139]|new[140]	_	_
11-58	2623-2635	microsensors	object[139]|object[140]	giv[139]|new[140]	_	_
11-59	2636-2637	,	_	_	_	_
11-60	2638-2641	was	_	_	_	_
11-61	2642-2651	developed	_	_	_	_
11-62	2652-2653	.	_	_	_	_

#Text=The binding activity of the immobilized Con A was assessed by measuring the intensity from fluorescent labelled dextran ( FITC and Alexa 488 ; with a surface coverage ranging from 1.8 × 1011 to 2.1 × 1012 immobilized fluorescent molecules per cm2 ) over a glucose concentration range from 0 to 40 mM , whereas any structural changes to the surface topography were investigated using AFM .
12-1	2654-2657	The	abstract[142]	new[142]	coref	16-1[219_142]
12-2	2658-2665	binding	object|abstract[142]	giv|new[142]	_	_
12-3	2666-2674	activity	abstract[142]	new[142]	_	_
12-4	2675-2677	of	abstract[142]	new[142]	_	_
12-5	2678-2681	the	abstract[142]	new[142]	_	_
12-6	2682-2693	immobilized	abstract[142]	new[142]	_	_
12-7	2694-2697	Con	abstract[142]	new[142]	_	_
12-8	2698-2699	A	abstract[142]	new[142]	_	_
12-9	2700-2703	was	_	_	_	_
12-10	2704-2712	assessed	_	_	_	_
12-11	2713-2715	by	_	_	_	_
12-12	2716-2725	measuring	_	_	_	_
12-13	2726-2729	the	abstract[143]	new[143]	coref	13-9[165_143]
12-14	2730-2739	intensity	abstract[143]	new[143]	_	_
12-15	2740-2744	from	abstract[143]	new[143]	_	_
12-16	2745-2756	fluorescent	abstract[143]	new[143]	_	_
12-17	2757-2765	labelled	_	_	_	_
12-18	2766-2773	dextran	substance	giv	coref	13-32
12-19	2774-2775	(	_	_	_	_
12-20	2776-2780	FITC	abstract	new	_	_
12-21	2781-2784	and	_	_	_	_
12-22	2785-2790	Alexa	abstract[146]	new[146]	_	_
12-23	2791-2794	488	abstract[146]|quantity	new[146]|new	_	_
12-24	2795-2796	;	_	_	_	_
12-25	2797-2801	with	_	_	_	_
12-26	2802-2803	a	abstract[149]	new[149]	_	_
12-27	2804-2811	surface	place|abstract[149]	giv|new[149]	coref	12-61
12-28	2812-2820	coverage	abstract[149]	new[149]	_	_
12-29	2821-2828	ranging	_	_	_	_
12-30	2829-2833	from	_	_	_	_
12-31	2834-2837	1.8	_	_	_	_
12-32	2838-2839	×	_	_	_	_
12-33	2840-2844	1011	_	_	_	_
12-34	2845-2847	to	_	_	_	_
12-35	2848-2851	2.1	object[151]	new[151]	coref	19-40[253_151]
12-36	2852-2853	×	object[151]	new[151]	_	_
12-37	2854-2858	1012	quantity|object[151]	new|new[151]	_	_
12-38	2859-2870	immobilized	object[151]	new[151]	_	_
12-39	2871-2882	fluorescent	object[151]	new[151]	_	_
12-40	2883-2892	molecules	object[151]	new[151]	_	_
12-41	2893-2896	per	object[151]	new[151]	_	_
12-42	2897-2900	cm2	object[151]|quantity	new[151]|new	_	_
12-43	2901-2902	)	object[151]	new[151]	_	_
12-44	2903-2907	over	object[151]	new[151]	_	_
12-45	2908-2909	a	object[151]|abstract[155]	new[151]|giv[155]	coref	17-12[229_155]
12-46	2910-2917	glucose	object[151]|substance|abstract[155]	new[151]|giv|giv[155]	_	_
12-47	2918-2931	concentration	object[151]|abstract|abstract[155]	new[151]|new|giv[155]	_	_
12-48	2932-2937	range	object[151]|abstract[155]	new[151]|giv[155]	_	_
12-49	2938-2942	from	object[151]|abstract[155]	new[151]|giv[155]	_	_
12-50	2943-2944	0	object[151]|abstract[155]|quantity	new[151]|giv[155]|new	_	_
12-51	2945-2947	to	object[151]|abstract[155]	new[151]|giv[155]	_	_
12-52	2948-2950	40	object[151]|abstract[155]|quantity[157]	new[151]|giv[155]|new[157]	_	_
12-53	2951-2953	mM	object[151]|abstract[155]|quantity[157]	new[151]|giv[155]|new[157]	_	_
12-54	2954-2955	,	_	_	_	_
12-55	2956-2963	whereas	_	_	_	_
12-56	2964-2967	any	abstract[158]	new[158]	_	_
12-57	2968-2978	structural	abstract[158]	new[158]	_	_
12-58	2979-2986	changes	abstract[158]	new[158]	_	_
12-59	2987-2989	to	abstract[158]	new[158]	_	_
12-60	2990-2993	the	abstract[158]|abstract[160]	new[158]|new[160]	_	_
12-61	2994-3001	surface	abstract[158]|place|abstract[160]	new[158]|giv|new[160]	coref	13-20
12-62	3002-3012	topography	abstract[158]|abstract[160]	new[158]|new[160]	_	_
12-63	3013-3017	were	_	_	_	_
12-64	3018-3030	investigated	_	_	_	_
12-65	3031-3036	using	_	_	_	_
12-66	3037-3040	AFM	event	new	_	_
12-67	3041-3042	.	_	_	_	_

#Text=These complementing measurements verified that a change in the fluorescence intensity was accompanied with a change in the average surface roughness , and thereby the composition ( addition and loss of dextran ) at the sample surface .
13-1	3043-3048	These	abstract[162]	new[162]	coref	18-16[238_162]
13-2	3049-3062	complementing	abstract[162]	new[162]	_	_
13-3	3063-3075	measurements	abstract[162]	new[162]	_	_
13-4	3076-3084	verified	_	_	_	_
13-5	3085-3089	that	_	_	_	_
13-6	3090-3091	a	abstract[163]	new[163]	_	_
13-7	3092-3098	change	abstract[163]	new[163]	_	_
13-8	3099-3101	in	abstract[163]	new[163]	_	_
13-9	3102-3105	the	abstract[163]|abstract[165]	new[163]|giv[165]	_	_
13-10	3106-3118	fluorescence	abstract[163]|abstract|abstract[165]	new[163]|new|giv[165]	_	_
13-11	3119-3128	intensity	abstract[163]|abstract[165]	new[163]|giv[165]	_	_
13-12	3129-3132	was	_	_	_	_
13-13	3133-3144	accompanied	_	_	_	_
13-14	3145-3149	with	_	_	_	_
13-15	3150-3151	a	abstract[166]	new[166]	coref	16-20[225_166]
13-16	3152-3158	change	abstract[166]	new[166]	_	_
13-17	3159-3161	in	abstract[166]	new[166]	_	_
13-18	3162-3165	the	abstract[166]|abstract[168]	new[166]|new[168]	_	_
13-19	3166-3173	average	abstract[166]|abstract[168]	new[166]|new[168]	_	_
13-20	3174-3181	surface	abstract[166]|place|abstract[168]	new[166]|giv|new[168]	coref	13-35[174_0]
13-21	3182-3191	roughness	abstract[166]|abstract[168]	new[166]|new[168]	_	_
13-22	3192-3193	,	_	_	_	_
13-23	3194-3197	and	_	_	_	_
13-24	3198-3205	thereby	abstract[169]	giv[169]	_	_
13-25	3206-3209	the	abstract[169]	giv[169]	_	_
13-26	3210-3221	composition	abstract[169]	giv[169]	_	_
13-27	3222-3223	(	_	_	_	_
13-28	3224-3232	addition	abstract	new	_	_
13-29	3233-3236	and	_	_	_	_
13-30	3237-3241	loss	abstract[171]	new[171]	_	_
13-31	3242-3244	of	abstract[171]	new[171]	_	_
13-32	3245-3252	dextran	abstract[171]|substance	new[171]|giv	_	_
13-33	3253-3254	)	abstract[171]	new[171]	_	_
13-34	3255-3257	at	abstract[171]	new[171]	_	_
13-35	3258-3261	the	abstract[171]|place[174]	new[171]|giv[174]	_	_
13-36	3262-3268	sample	abstract[171]|object|place[174]	new[171]|new|giv[174]	_	_
13-37	3269-3276	surface	abstract[171]|place[174]	new[171]|giv[174]	_	_
13-38	3277-3278	.	_	_	_	_

#Text=H. Aldewachi and coworkers in their paper on the Study of the Stability of Functionalized Gold Nanoparticles for the Colorimetric Detection of Dipeptidyl Peptidase IV report on three stabilization strategies of gold nanoparticles and their practical applications for the visual detection of dipeptidyl peptidase IV ( DPP-IV ) , an enzyme of high clinical importance , especially as a diagnostic and prognostic marker of various inflammatory disorders and tumors .
14-1	3279-3281	H.	person[175]	new[175]	_	_
14-2	3282-3291	Aldewachi	person[175]	new[175]	_	_
14-3	3292-3295	and	_	_	_	_
14-4	3296-3305	coworkers	person[176]	giv[176]	_	_
14-5	3306-3308	in	person[176]	giv[176]	_	_
14-6	3309-3314	their	person[176]|abstract[177]	giv[176]|giv[177]	_	_
14-7	3315-3320	paper	person[176]|abstract[177]	giv[176]|giv[177]	_	_
14-8	3321-3323	on	person[176]|abstract[177]	giv[176]|giv[177]	_	_
14-9	3324-3327	the	person[176]|abstract[177]|abstract[178]	giv[176]|giv[177]|new[178]	_	_
14-10	3328-3333	Study	person[176]|abstract[177]|abstract[178]	giv[176]|giv[177]|new[178]	_	_
14-11	3334-3336	of	person[176]|abstract[177]|abstract[178]	giv[176]|giv[177]|new[178]	_	_
14-12	3337-3340	the	person[176]|abstract[177]|abstract[178]|abstract[179]	giv[176]|giv[177]|new[178]|new[179]	coref	15-38[214_179]
14-13	3341-3350	Stability	person[176]|abstract[177]|abstract[178]|abstract[179]	giv[176]|giv[177]|new[178]|new[179]	_	_
14-14	3351-3353	of	person[176]|abstract[177]|abstract[178]|abstract[179]	giv[176]|giv[177]|new[178]|new[179]	_	_
14-15	3354-3368	Functionalized	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]	giv[176]|giv[177]|new[178]|new[179]|giv[181]	_	_
14-16	3369-3373	Gold	person[176]|abstract[177]|abstract[178]|abstract[179]|substance|object[181]	giv[176]|giv[177]|new[178]|new[179]|new|giv[181]	coref	14-32
14-17	3374-3387	Nanoparticles	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]	giv[176]|giv[177]|new[178]|new[179]|giv[181]	_	_
14-18	3388-3391	for	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]	giv[176]|giv[177]|new[178]|new[179]|giv[181]	_	_
14-19	3392-3395	the	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]	_	_
14-20	3396-3408	Colorimetric	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract|abstract[183]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|new|giv[183]	_	_
14-21	3409-3418	Detection	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]	_	_
14-22	3419-3421	of	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]	_	_
14-23	3422-3432	Dipeptidyl	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract|abstract[185]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|new|new[185]	coref|coref	14-43|14-43
14-24	3433-3442	Peptidase	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[185]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|new[185]	_	_
14-25	3443-3445	IV	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|person	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|new	_	_
14-26	3446-3452	report	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]	_	_
14-27	3453-3455	on	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]	_	_
14-28	3456-3461	three	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[188]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|new[188]	_	_
14-29	3462-3475	stabilization	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract|abstract[188]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|new|new[188]	_	_
14-30	3476-3486	strategies	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[188]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|new[188]	_	_
14-31	3487-3489	of	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[188]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|new[188]	_	_
14-32	3490-3494	gold	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[188]|substance	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|new[188]|giv	_	_
14-33	3495-3508	nanoparticles	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[188]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|new[188]	_	_
14-34	3509-3512	and	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]	_	_
14-35	3513-3518	their	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[190]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|giv[190]	_	_
14-36	3519-3528	practical	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[190]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|giv[190]	_	_
14-37	3529-3541	applications	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[190]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|giv[190]	_	_
14-38	3542-3545	for	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[190]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|giv[190]	_	_
14-39	3546-3549	the	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[190]|abstract[191]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|giv[190]|new[191]	_	_
14-40	3550-3556	visual	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[190]|abstract[191]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|giv[190]|new[191]	_	_
14-41	3557-3566	detection	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[190]|abstract[191]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|giv[190]|new[191]	_	_
14-42	3567-3569	of	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[190]|abstract[191]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|giv[190]|new[191]	_	_
14-43	3570-3580	dipeptidyl	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[190]|abstract[191]|substance|object[194]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|giv[190]|new[191]|giv|new[194]	appos|appos	14-47[0_194]|14-47[0_194]
14-44	3581-3590	peptidase	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[190]|abstract[191]|substance|object[194]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|giv[190]|new[191]|new|new[194]	_	_
14-45	3591-3593	IV	person[176]|abstract[177]|abstract[178]|abstract[179]|object[181]|abstract[183]|abstract[190]|abstract[191]|object[194]	giv[176]|giv[177]|new[178]|new[179]|giv[181]|giv[183]|giv[190]|new[191]|new[194]	_	_
14-46	3594-3595	(	_	_	_	_
14-47	3596-3602	DPP-IV	object	giv	coref	18-25
14-48	3603-3604	)	_	_	_	_
14-49	3605-3606	,	_	_	_	_
14-50	3607-3609	an	substance[196]	new[196]	_	_
14-51	3610-3616	enzyme	substance[196]	new[196]	_	_
14-52	3617-3619	of	substance[196]	new[196]	_	_
14-53	3620-3624	high	substance[196]|abstract[197]	new[196]|new[197]	_	_
14-54	3625-3633	clinical	substance[196]|abstract[197]	new[196]|new[197]	_	_
14-55	3634-3644	importance	substance[196]|abstract[197]	new[196]|new[197]	_	_
14-56	3645-3646	,	_	_	_	_
14-57	3647-3657	especially	abstract[198]	new[198]	_	_
14-58	3658-3660	as	abstract[198]	new[198]	_	_
14-59	3661-3662	a	abstract[198]	new[198]	_	_
14-60	3663-3673	diagnostic	abstract[198]	new[198]	_	_
14-61	3674-3677	and	abstract[198]	new[198]	_	_
14-62	3678-3688	prognostic	abstract[198]	new[198]	_	_
14-63	3689-3695	marker	abstract[198]	new[198]	_	_
14-64	3696-3698	of	abstract[198]	new[198]	_	_
14-65	3699-3706	various	abstract[198]|abstract[199]	new[198]|new[199]	_	_
14-66	3707-3719	inflammatory	abstract[198]|abstract[199]	new[198]|new[199]	_	_
14-67	3720-3729	disorders	abstract[198]|abstract[199]	new[198]|new[199]	_	_
14-68	3730-3733	and	abstract[198]	new[198]	_	_
14-69	3734-3740	tumors	abstract[198]|abstract	new[198]|new	_	_
14-70	3741-3742	.	_	_	_	_

#Text=The first strategy used the incorporation of a PEGylated sequence with a dithiol anchor to create biorecognition ligands ; the other two strategies used a peptide sequence ( CALNN ) selected from 58 peptide sequences tested for their high stability and resistance to electrolyte-induced Au NP aggregation .
15-1	3743-3746	The	abstract[201]	new[201]	_	_
15-2	3747-3752	first	abstract[201]	new[201]	_	_
15-3	3753-3761	strategy	abstract[201]	new[201]	_	_
15-4	3762-3766	used	_	_	_	_
15-5	3767-3770	the	abstract[202]	new[202]	_	_
15-6	3771-3784	incorporation	abstract[202]	new[202]	_	_
15-7	3785-3787	of	abstract[202]	new[202]	_	_
15-8	3788-3789	a	abstract[202]|abstract[203]	new[202]|new[203]	coref	15-25[209_203]
15-9	3790-3799	PEGylated	abstract[202]|abstract[203]	new[202]|new[203]	_	_
15-10	3800-3808	sequence	abstract[202]|abstract[203]	new[202]|new[203]	_	_
15-11	3809-3813	with	abstract[202]|abstract[203]	new[202]|new[203]	_	_
15-12	3814-3815	a	abstract[202]|abstract[203]|object[205]	new[202]|new[203]|new[205]	_	_
15-13	3816-3823	dithiol	abstract[202]|abstract[203]|abstract|object[205]	new[202]|new[203]|new|new[205]	_	_
15-14	3824-3830	anchor	abstract[202]|abstract[203]|object[205]	new[202]|new[203]|new[205]	_	_
15-15	3831-3833	to	_	_	_	_
15-16	3834-3840	create	_	_	_	_
15-17	3841-3855	biorecognition	abstract[206]	new[206]	_	_
15-18	3856-3863	ligands	abstract[206]	new[206]	_	_
15-19	3864-3865	;	_	_	_	_
15-20	3866-3869	the	abstract[207]	new[207]	_	_
15-21	3870-3875	other	abstract[207]	new[207]	_	_
15-22	3876-3879	two	abstract[207]	new[207]	_	_
15-23	3880-3890	strategies	abstract[207]	new[207]	_	_
15-24	3891-3895	used	_	_	_	_
15-25	3896-3897	a	abstract[209]	giv[209]	_	_
15-26	3898-3905	peptide	abstract|abstract[209]	giv|giv[209]	coref	15-34
15-27	3906-3914	sequence	abstract[209]	giv[209]	_	_
15-28	3915-3916	(	_	_	_	_
15-29	3917-3922	CALNN	object	new	_	_
15-30	3923-3924	)	_	_	_	_
15-31	3925-3933	selected	_	_	_	_
15-32	3934-3938	from	_	_	_	_
15-33	3939-3941	58	abstract[212]	new[212]	ana	15-38[0_212]
15-34	3942-3949	peptide	abstract|abstract[212]	giv|new[212]	_	_
15-35	3950-3959	sequences	abstract[212]	new[212]	_	_
15-36	3960-3966	tested	_	_	_	_
15-37	3967-3970	for	_	_	_	_
15-38	3971-3976	their	abstract|abstract[214]	giv|giv[214]	coref|coref	17-22[232_214]|17-22[232_214]
15-39	3977-3981	high	abstract[214]	giv[214]	_	_
15-40	3982-3991	stability	abstract[214]	giv[214]	_	_
15-41	3992-3995	and	_	_	_	_
15-42	3996-4006	resistance	abstract[215]	new[215]	_	_
15-43	4007-4009	to	abstract[215]	new[215]	_	_
15-44	4010-4029	electrolyte-induced	abstract[215]|abstract[218]	new[215]|new[218]	_	_
15-45	4030-4032	Au	abstract[215]|person|abstract[218]	new[215]|new|new[218]	_	_
15-46	4033-4035	NP	abstract[215]|organization|abstract[218]	new[215]|new|new[218]	_	_
15-47	4036-4047	aggregation	abstract[215]|abstract[218]	new[215]|new[218]	_	_
15-48	4048-4049	.	_	_	_	_

#Text=DPP-IV/CD26 activity using the three approaches was detected under optimal conditions and only C/G-capped AuNPs showed a response with a color change when incubated with DPP-IV/CD26 .
16-1	4050-4061	DPP-IV/CD26	abstract[219]	giv[219]	coref	18-25[241_219]
16-2	4062-4070	activity	abstract[219]	giv[219]	_	_
16-3	4071-4076	using	_	_	_	_
16-4	4077-4080	the	abstract[220]	new[220]	_	_
16-5	4081-4086	three	abstract[220]	new[220]	_	_
16-6	4087-4097	approaches	abstract[220]	new[220]	_	_
16-7	4098-4101	was	_	_	_	_
16-8	4102-4110	detected	_	_	_	_
16-9	4111-4116	under	_	_	_	_
16-10	4117-4124	optimal	abstract[221]	new[221]	coref	20-7[265_221]
16-11	4125-4135	conditions	abstract[221]	new[221]	_	_
16-12	4136-4139	and	_	_	_	_
16-13	4140-4144	only	abstract[222]	new[222]	coref	17-1[227_222]
16-14	4145-4155	C/G-capped	abstract[222]	new[222]	_	_
16-15	4156-4161	AuNPs	abstract[222]	new[222]	_	_
16-16	4162-4168	showed	_	_	_	_
16-17	4169-4170	a	abstract[223]	new[223]	_	_
16-18	4171-4179	response	abstract[223]	new[223]	_	_
16-19	4180-4184	with	abstract[223]	new[223]	_	_
16-20	4185-4186	a	abstract[223]|abstract[225]	new[223]|giv[225]	_	_
16-21	4187-4192	color	abstract[223]|abstract|abstract[225]	new[223]|new|giv[225]	_	_
16-22	4193-4199	change	abstract[223]|abstract[225]	new[223]|giv[225]	_	_
16-23	4200-4204	when	_	_	_	_
16-24	4205-4214	incubated	_	_	_	_
16-25	4215-4219	with	_	_	_	_
16-26	4220-4231	DPP-IV/CD26	abstract	new	_	_
16-27	4232-4233	.	_	_	_	_

#Text=C/G-capped AuNPs were less sensitive than the monofunctionalized systems , with a dynamic range of 10 – 30 U/L but with very high stability in ionic solutions .
17-1	4234-4244	C/G-capped	abstract[227]	giv[227]	_	_
17-2	4245-4250	AuNPs	abstract[227]	giv[227]	_	_
17-3	4251-4255	were	_	_	_	_
17-4	4256-4260	less	_	_	_	_
17-5	4261-4270	sensitive	_	_	_	_
17-6	4271-4275	than	_	_	_	_
17-7	4276-4279	the	object[228]	giv[228]	_	_
17-8	4280-4298	monofunctionalized	object[228]	giv[228]	_	_
17-9	4299-4306	systems	object[228]	giv[228]	_	_
17-10	4307-4308	,	_	_	_	_
17-11	4309-4313	with	_	_	_	_
17-12	4314-4315	a	abstract[229]	giv[229]	_	_
17-13	4316-4323	dynamic	abstract[229]	giv[229]	_	_
17-14	4324-4329	range	abstract[229]	giv[229]	_	_
17-15	4330-4332	of	abstract[229]	giv[229]	_	_
17-16	4333-4335	10	abstract[229]|quantity	giv[229]|new	_	_
17-17	4336-4337	–	abstract[229]	giv[229]	_	_
17-18	4338-4340	30	abstract[229]|quantity[231]	giv[229]|new[231]	_	_
17-19	4341-4344	U/L	abstract[229]|quantity[231]	giv[229]|new[231]	_	_
17-20	4345-4348	but	_	_	_	_
17-21	4349-4353	with	_	_	_	_
17-22	4354-4358	very	abstract[232]	giv[232]	_	_
17-23	4359-4363	high	abstract[232]	giv[232]	_	_
17-24	4364-4373	stability	abstract[232]	giv[232]	_	_
17-25	4374-4376	in	abstract[232]	giv[232]	_	_
17-26	4377-4382	ionic	abstract[232]|substance[233]	giv[232]|new[233]	_	_
17-27	4383-4392	solutions	abstract[232]|substance[233]	giv[232]|new[233]	_	_
17-28	4393-4394	.	_	_	_	_

#Text=The developed biofunctionalized assay was successfully evaluated by gel electrophoresis , zeta potential , and hydrodynamic radius measurements and tested for the assay of DPP-IV activity .
18-1	4395-4398	The	object[234]	new[234]	coref	18-22[239_234]
18-2	4399-4408	developed	object[234]	new[234]	_	_
18-3	4409-4426	biofunctionalized	object[234]	new[234]	_	_
18-4	4427-4432	assay	object[234]	new[234]	_	_
18-5	4433-4436	was	_	_	_	_
18-6	4437-4449	successfully	_	_	_	_
18-7	4450-4459	evaluated	_	_	_	_
18-8	4460-4462	by	_	_	_	_
18-9	4463-4466	gel	substance|object[236]	new|new[236]	_	_
18-10	4467-4482	electrophoresis	object[236]	new[236]	_	_
18-11	4483-4484	,	_	_	_	_
18-12	4485-4489	zeta	_	_	_	_
18-13	4490-4499	potential	_	_	_	_
18-14	4500-4501	,	_	_	_	_
18-15	4502-4505	and	_	_	_	_
18-16	4506-4518	hydrodynamic	abstract[238]	giv[238]	_	_
18-17	4519-4525	radius	abstract|abstract[238]	new|giv[238]	_	_
18-18	4526-4538	measurements	abstract[238]	giv[238]	_	_
18-19	4539-4542	and	_	_	_	_
18-20	4543-4549	tested	_	_	_	_
18-21	4550-4553	for	_	_	_	_
18-22	4554-4557	the	object[239]	giv[239]	_	_
18-23	4558-4563	assay	object[239]	giv[239]	_	_
18-24	4564-4566	of	object[239]	giv[239]	_	_
18-25	4567-4573	DPP-IV	object[239]|place|abstract[241]	giv[239]|giv|giv[241]	_	_
18-26	4574-4582	activity	object[239]|abstract[241]	giv[239]|giv[241]	_	_
18-27	4583-4584	.	_	_	_	_

#Text=Finally , in the review : Biosensor Applications of Electrodeposited Nanostructures , the author K.J. Stine traces an overview on the area of developing biosensors based on electrodeposited nanostructures , which has many possible applications to the detection of small molecules , metabolites , protein antigens , oligonucleotides , and other targets , including bacteria and viruses .
19-1	4585-4592	Finally	_	_	_	_
19-2	4593-4594	,	_	_	_	_
19-3	4595-4597	in	_	_	_	_
19-4	4598-4601	the	abstract[242]	new[242]	appos	19-7[244_242]
19-5	4602-4608	review	abstract[242]	new[242]	_	_
19-6	4609-4610	:	_	_	_	_
19-7	4611-4620	Biosensor	person|abstract[244]	giv|giv[244]	coref|coref	19-33[251_244]|19-33[251_244]
19-8	4621-4633	Applications	abstract[244]	giv[244]	_	_
19-9	4634-4636	of	abstract[244]	giv[244]	_	_
19-10	4637-4653	Electrodeposited	abstract[244]|object[245]	giv[244]|new[245]	coref	19-28[250_245]
19-11	4654-4668	Nanostructures	abstract[244]|object[245]	giv[244]|new[245]	_	_
19-12	4669-4670	,	_	_	_	_
19-13	4671-4674	the	person[246]	new[246]	_	_
19-14	4675-4681	author	person[246]	new[246]	_	_
19-15	4682-4686	K.J.	person[246]	new[246]	_	_
19-16	4687-4692	Stine	person[246]	new[246]	_	_
19-17	4693-4699	traces	_	_	_	_
19-18	4700-4702	an	abstract[247]	new[247]	_	_
19-19	4703-4711	overview	abstract[247]	new[247]	_	_
19-20	4712-4714	on	abstract[247]	new[247]	_	_
19-21	4715-4718	the	abstract[247]|abstract[248]	new[247]|new[248]	_	_
19-22	4719-4723	area	abstract[247]|abstract[248]	new[247]|new[248]	_	_
19-23	4724-4726	of	_	_	_	_
19-24	4727-4737	developing	_	_	_	_
19-25	4738-4748	biosensors	substance	giv	_	_
19-26	4749-4754	based	_	_	_	_
19-27	4755-4757	on	_	_	_	_
19-28	4758-4774	electrodeposited	object[250]	giv[250]	_	_
19-29	4775-4789	nanostructures	object[250]	giv[250]	_	_
19-30	4790-4791	,	_	_	_	_
19-31	4792-4797	which	_	_	_	_
19-32	4798-4801	has	_	_	_	_
19-33	4802-4806	many	abstract[251]	giv[251]	_	_
19-34	4807-4815	possible	abstract[251]	giv[251]	_	_
19-35	4816-4828	applications	abstract[251]	giv[251]	_	_
19-36	4829-4831	to	abstract[251]	giv[251]	_	_
19-37	4832-4835	the	abstract[251]|abstract[252]	giv[251]|new[252]	_	_
19-38	4836-4845	detection	abstract[251]|abstract[252]	giv[251]|new[252]	_	_
19-39	4846-4848	of	abstract[251]|abstract[252]	giv[251]|new[252]	_	_
19-40	4849-4854	small	abstract[251]|abstract[252]|object[253]	giv[251]|new[252]|giv[253]	_	_
19-41	4855-4864	molecules	abstract[251]|abstract[252]|object[253]	giv[251]|new[252]|giv[253]	_	_
19-42	4865-4866	,	abstract[251]|abstract[252]	giv[251]|new[252]	_	_
19-43	4867-4878	metabolites	abstract[251]|abstract[252]|substance	giv[251]|new[252]|new	_	_
19-44	4879-4880	,	abstract[251]|abstract[252]	giv[251]|new[252]	_	_
19-45	4881-4888	protein	abstract[251]|abstract[252]|substance|substance[256]	giv[251]|new[252]|giv|new[256]	_	_
19-46	4889-4897	antigens	abstract[251]|abstract[252]|substance[256]	giv[251]|new[252]|new[256]	_	_
19-47	4898-4899	,	abstract[251]|abstract[252]	giv[251]|new[252]	_	_
19-48	4900-4916	oligonucleotides	abstract[251]|abstract[252]|substance	giv[251]|new[252]|new	coref	21-21[275_0]
19-49	4917-4918	,	abstract[251]|abstract[252]	giv[251]|new[252]	_	_
19-50	4919-4922	and	abstract[251]|abstract[252]	giv[251]|new[252]	_	_
19-51	4923-4928	other	abstract[251]|abstract[252]|abstract[258]	giv[251]|new[252]|new[258]	coref	21-1[268_258]
19-52	4929-4936	targets	abstract[251]|abstract[252]|abstract[258]	giv[251]|new[252]|new[258]	_	_
19-53	4937-4938	,	abstract[251]|abstract[252]|abstract[258]	giv[251]|new[252]|new[258]	_	_
19-54	4939-4948	including	abstract[251]|abstract[252]|abstract[258]	giv[251]|new[252]|new[258]	_	_
19-55	4949-4957	bacteria	abstract[251]|abstract[252]|abstract[258]|animal	giv[251]|new[252]|new[258]|new	_	_
19-56	4958-4961	and	abstract[251]|abstract[252]|abstract[258]	giv[251]|new[252]|new[258]	_	_
19-57	4962-4969	viruses	abstract[251]|abstract[252]|abstract[258]|animal	giv[251]|new[252]|new[258]|new	_	_
19-58	4970-4971	.	_	_	_	_

#Text=The variety of substrate electrodes and preparation conditions can produce a vast range of structures .
20-1	4972-4975	The	abstract[261]	new[261]	_	_
20-2	4976-4983	variety	abstract[261]	new[261]	_	_
20-3	4984-4986	of	abstract[261]	new[261]	_	_
20-4	4987-4996	substrate	abstract[261]|object|object[263]	new[261]|giv|giv[263]	_	_
20-5	4997-5007	electrodes	abstract[261]|object[263]	new[261]|giv[263]	_	_
20-6	5008-5011	and	abstract[261]|object[263]	new[261]|giv[263]	_	_
20-7	5012-5023	preparation	abstract[261]|object[263]|abstract|abstract[265]	new[261]|giv[263]|new|giv[265]	_	_
20-8	5024-5034	conditions	abstract[261]|object[263]|abstract[265]	new[261]|giv[263]|giv[265]	_	_
20-9	5035-5038	can	_	_	_	_
20-10	5039-5046	produce	_	_	_	_
20-11	5047-5048	a	abstract[266]	new[266]	_	_
20-12	5049-5053	vast	abstract[266]	new[266]	_	_
20-13	5054-5059	range	abstract[266]	new[266]	_	_
20-14	5060-5062	of	abstract[266]	new[266]	_	_
20-15	5063-5073	structures	abstract[266]|abstract	new[266]|new	_	_
20-16	5074-5075	.	_	_	_	_

#Text=Many additional targets of high interest for the development of diagnostics , such as glycoproteins , circulating tumor cells , circulating oligonucleotides , microRNAs , and content in microvesicles remain unexplored .
21-1	5076-5080	Many	abstract[268]	giv[268]	_	_
21-2	5081-5091	additional	abstract[268]	giv[268]	_	_
21-3	5092-5099	targets	abstract[268]	giv[268]	_	_
21-4	5100-5102	of	abstract[268]	giv[268]	_	_
21-5	5103-5107	high	abstract[268]|abstract[269]	giv[268]|new[269]	_	_
21-6	5108-5116	interest	abstract[268]|abstract[269]	giv[268]|new[269]	_	_
21-7	5117-5120	for	abstract[268]|abstract[269]	giv[268]|new[269]	_	_
21-8	5121-5124	the	abstract[268]|abstract[269]|abstract[270]	giv[268]|new[269]|new[270]	_	_
21-9	5125-5136	development	abstract[268]|abstract[269]|abstract[270]	giv[268]|new[269]|new[270]	_	_
21-10	5137-5139	of	abstract[268]|abstract[269]|abstract[270]	giv[268]|new[269]|new[270]	_	_
21-11	5140-5151	diagnostics	abstract[268]|abstract[269]|abstract[270]|abstract	giv[268]|new[269]|new[270]|new	_	_
21-12	5152-5153	,	abstract[268]|abstract[269]|abstract[270]	giv[268]|new[269]|new[270]	_	_
21-13	5154-5158	such	abstract[268]|abstract[269]|abstract[270]	giv[268]|new[269]|new[270]	_	_
21-14	5159-5161	as	abstract[268]|abstract[269]|abstract[270]	giv[268]|new[269]|new[270]	_	_
21-15	5162-5175	glycoproteins	abstract[268]|abstract[269]|abstract[270]|substance	giv[268]|new[269]|new[270]|new	_	_
21-16	5176-5177	,	abstract[268]|abstract[269]|abstract[270]	giv[268]|new[269]|new[270]	_	_
21-17	5178-5189	circulating	abstract[268]|abstract[269]|abstract[270]	giv[268]|new[269]|new[270]	_	_
21-18	5190-5195	tumor	abstract[268]|abstract[269]|abstract[270]|abstract|object[274]	giv[268]|new[269]|new[270]|new|giv[274]	_	_
21-19	5196-5201	cells	abstract[268]|abstract[269]|abstract[270]|object[274]	giv[268]|new[269]|new[270]|giv[274]	_	_
21-20	5202-5203	,	abstract[268]|abstract[269]|abstract[270]	giv[268]|new[269]|new[270]	_	_
21-21	5204-5215	circulating	abstract[268]|abstract[269]|abstract[270]|substance[275]	giv[268]|new[269]|new[270]|giv[275]	_	_
21-22	5216-5232	oligonucleotides	abstract[268]|abstract[269]|abstract[270]|substance[275]	giv[268]|new[269]|new[270]|giv[275]	_	_
21-23	5233-5234	,	abstract[268]|abstract[269]|abstract[270]	giv[268]|new[269]|new[270]	_	_
21-24	5235-5244	microRNAs	abstract[268]|abstract[269]|abstract[270]|object	giv[268]|new[269]|new[270]|new	_	_
21-25	5245-5246	,	abstract[268]|abstract[269]|abstract[270]	giv[268]|new[269]|new[270]	_	_
21-26	5247-5250	and	abstract[268]|abstract[269]|abstract[270]	giv[268]|new[269]|new[270]	_	_
21-27	5251-5258	content	abstract[268]|abstract[269]|abstract[270]|abstract[277]	giv[268]|new[269]|new[270]|new[277]	_	_
21-28	5259-5261	in	abstract[268]|abstract[269]|abstract[270]|abstract[277]	giv[268]|new[269]|new[270]|new[277]	_	_
21-29	5262-5275	microvesicles	abstract[268]|abstract[269]|abstract[270]|abstract[277]|object	giv[268]|new[269]|new[270]|new[277]|new	_	_
21-30	5276-5282	remain	_	_	_	_
21-31	5283-5293	unexplored	_	_	_	_
21-32	5294-5295	.	_	_	_	_
